Events or circumstances that raise substantial doubt about the going-concern assumption
ADR Biomedical Holdings Inc. and the ADR Biomedical Holdings Inc. group, including consolidated subsidiary ＡＤＲセラピューティクス㈱
Cellution centrifuge, Cell Therapy Kit, Cellution Therapy Kit SUI, and Neocella (formerly known as CrymEX)
As a research and development-driven company, the company requires substantial research and development funding. The burden of research and development expenses has prolonged the period of upfront investment, resulting in recurring operating losses and negative operating cash flow. In addition, the method, amount and timing of further financing have not been determined.
Operating loss: ¥91.818 million; ordinary loss: ¥93.281 million; quarterly net loss attributable to owners of the parent: ¥93.674 million; net assets: negative ¥71.691 million
Cumulative consolidated period for the first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026)
There is no change to the full-year consolidated earnings forecast announced on 15 May 2026.
The company will advance its research and development activities, transition to domestic production of its products, expand its business into new fields, reduce expenses, improve its financial position and secure financing. Sales are expected to increase significantly through sales of domestically produced centrifuges from October 2026 onward, and the company is expected to enter the full-scale sales phase during the fiscal year ending March 2027. The method, amount and timing of further financing have not been determined.
| Item | Details |
|---|---|
| Event name | Events or circumstances that raise substantial doubt about the going-concern assumption |
| Date of occurrence | 30 June 2026 (the continuation of these conditions was confirmed as of the end of the first quarter of the fiscal year ending March 2027) |
| Date recognized / date notice received | 30 June 2026 (the company recognized the conditions as of the end of the first quarter of the fiscal year ending March 2027) |
| Subject Entity | ADR Biomedical Holdings Inc. and the ADR Biomedical Holdings Inc. group, including consolidated subsidiary ＡＤＲセラピューティクス㈱ |
| Target Locations / Products | Cellution centrifuge, Cell Therapy Kit, Cellution Therapy Kit SUI, and Neocella (formerly known as CrymEX) |
| Cause | As a research and development-driven company, the company requires substantial research and development funding. The burden of research and development expenses has prolonged the period of upfront investment, resulting in recurring operating losses and negative operating cash flow. In addition, the method, amount and timing of further financing have not been determined. |
| Amount of Impact on Business Performance | Operating loss: ¥91.818 million; ordinary loss: ¥93.281 million; quarterly net loss attributable to owners of the parent: ¥93.674 million; net assets: negative ¥71.691 million |
| Accounting period in which recognized | Cumulative consolidated period for the first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026) |
| Impact on Earnings Forecast | There is no change to the full-year consolidated earnings forecast announced on 15 May 2026. |
| Outlook | The company will advance its research and development activities, transition to domestic production of its products, expand its business into new fields, reduce expenses, improve its financial position and secure financing. Sales are expected to increase significantly through sales of domestically produced centrifuges from October 2026 onward, and the company is expected to enter the full-scale sales phase during the fiscal year ending March 2027. The method, amount and timing of further financing have not been determined. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As a research and development-driven company, the company requires substantial research and development funding, and its long-term upfront investment has resulted in recurring operating losses and negative operating cash flow. In addition, the method, amount and timing of future financing have not been determined.